These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20171670)

  • 1. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.
    Le BV; Griffin CR; Loeb S; Carvalhal GF; Kan D; Baumann NA; Catalona WJ
    J Urol; 2010 Apr; 183(4):1355-9. PubMed ID: 20171670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
    Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
    Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.
    Lazzeri M; Briganti A; Scattoni V; Lughezzani G; Larcher A; Gadda GM; Lista G; Cestari A; Buffi N; Bini V; Freschi M; Rigatti P; Montorsi F; Guazzoni G
    J Urol; 2012 Oct; 188(4):1137-43. PubMed ID: 22901578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
    Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
    BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
    Sokoll LJ; Wang Y; Feng Z; Kagan J; Partin AW; Sanda MG; Thompson IM; Chan DW
    J Urol; 2008 Aug; 180(2):539-43; discussion 543. PubMed ID: 18550118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
    Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
    Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.
    Ito K; Miyakubo M; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
    World J Urol; 2013 Apr; 31(2):305-11. PubMed ID: 22903772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
    Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
    Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
    BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml.
    Ito K; Yokomizo A; Tokunaga S; Arai G; Sugimoto M; Akakura K; Hasumi H; Sakai H; Ouraji A; Oki R; Kashiwagi E; Kobori Y; Hirama H; Kitoh H; Uemura H; Hakariya T; Suzuki K;
    J Urol; 2020 Jan; 203(1):83-91. PubMed ID: 31430244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
    Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
    Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
    Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
    Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.
    Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH
    J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography.
    Yu GP; Na R; Ye DW; Qi J; Liu F; Chen HT; Wu YS; Zhang GM; Sun JL; Zhu Y; Huang LQ; Ren SC; Jiang DK; Zheng SL; Jiang HW; Sun YH; Ding Q; Xu J
    Asian J Androl; 2016; 18(4):633-8. PubMed ID: 26975483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
    Abrate A; Lughezzani G; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Buffi N; Guazzoni G; Lazzeri M
    Korean J Urol; 2014 Jul; 55(7):436-45. PubMed ID: 25045441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.